Skip to content

Effect of transcutaneous aurical vagal nerve stimulation (taVNS) on fatigue in patients with long covid.

Effect of transcutaneous aurical vagal nerve stimulation (taVNS) on fatigue in patients with long covid. - CoviVa

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00031974
Enrollment
45
Registered
2023-05-25
Start date
2023-09-01
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U08.9 U09.9 U10.9 G93.3

Interventions

Group 1: Above-threshold-stimulation left tragus Group 2: Sub-threshold-stimulation left tragus Group 3: Sham-stimulation left tragus Group 4: Optional: Participants from Arm 2 and Arm 3 are permitted

Sponsors

Universitätsklinik Knappschaftskrankenhaus Bochum
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Z.n. completed Covid infection within the last 18 months - Fatigue persisting for = 3 months with a score =4 on the FSS fatigue scale - Age >18 - No depression or depression that has been treated stably for 4 weeks

Exclusion criteria

Exclusion criteria: - Serious psychiatric illness such as schizophrenia - Acute corona infection - >8 items on the NGASR suicide questionnaire - Vagus nerve stimulation or condition vagotomy - Relevant cardiac disease: bradycardiac cardiac arrhythmia (e.g. sick sinus syndrome), cardiac insufficiency, status post. Heart attack - Active implant such as cardiac pacemaker, defibrillator, neurostimulator, cochlear implant or drug delivery device and ventricular shunt. - Inability to understand the study - Progressive neurological disease (e.g. Parkinson's, MS, epilepsy) - pregnancy - Other acute illness associated with fatigue (e.g. cancer, chemotherapy, autoimmune diseases) - Polyneuropathy - Presence of a skin condition such as infection, psoriasis or eczema in the treatment area. - Presence of any anatomical abnormality that prevents the successful insertion of the ear electrode. - Presence of any serious medical condition that prevents successful participation in the study.

Design outcomes

Primary

MeasureTime frame
Acceptance of the therapy, effect of taVNS on MFI-20-Score

Secondary

MeasureTime frame
Effect of taVNS on BDI and SF36 score

Countries

Germany

Contacts

Public ContactMortimer Gierthmühlen

Universitätsklinik Knappschaftskrankenhaus Bochum

mortimer.gierthmuehlen@kk-bochum.de+492342990

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 3, 2026